Syncom Formulation (India) Share Price

17.230.02 (0.12%)
Volume: 5,04,672

Closed
Last Updated On: 08 Sep, 2025, 03:36 PM IST

STOCK SCORE

ETPrime Only

17.230.02 (0.12%)
Volume: 5,04,672

Syncom Form share price insights

View All

ROE Outperforming 5 Year Average
Company delivered ROE of 14.37% in year ending Mar 31, 2025 outperforming its 5 year avg. of 10.95%. (Source: Standalone Financials)
Quarterly Topline Performance
Company witnessed QoQ revenue decline of 21.1%, which is lowest in the last 3 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 74.22% outperformed its 3 year CAGR of 27.39%. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent less than 1% of its operating revenues towards interest expenses and 11.22% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
Syncom Form Share Price Update
Syncom Formulation (India) Ltd. share price moved up by 0.12% from its previous close of Rs 17.21. Syncom Formulation (India) Ltd. stock last traded price is 17.23
Share Price Value
Today/Current/Last 17.2317.25
Previous Day 17.2117.16

Share Price	Value
Today/Current/Last	17.2317.25
Previous Day	17.2117.16

InsightsSyncom Form

Do you find these insights useful?

hate it
meh
love it

Key Metrics

PE Ratio

(x)

28.14

EPS - TTM

(₹)

0.61

MCap

(₹ Cr.)

1,619.62

Sectoral MCap Rank

PB Ratio

(x)

4.73

Div Yield

(%)

0.00

Face Value

(₹)

1.00

Beta

VWAP

(₹)

17.23

52W H/L

(₹)

27.90 / 14.10

Syncom Form Share Price Returns

1 Day	0.12%
1 Week	3.17%
1 Month	-5.69%
3 Months	-16.92%
1 Year	-25.51%
3 Years	N.A.
5 Years	N.A.

ET Stock ScreenersTop Score Companies

Check whether Syncom Form belongs to analysts' top-rated companies list?

View Stock Screeners

Syncom Form News & Analysis

View all Syncom Form Share News & Announcements

Syncom Form Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

View Stock Score on a 10-point scale
See ratings on Earning, Fundamentals, Valuation, Risk & Price
Check stock performance

JOIN ET PRIME

Syncom Form Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

Syncom Form Financials

Insights

Quarterly Topline Performance
Company witnessed QoQ revenue decline of 21.1%, which is lowest in the last 3 years. (Source: Consolidated Financials)
Beating 3 Yr Revenue CAGR
Company's annual revenue growth of 74.22% outperformed its 3 year CAGR of 27.39%. (Source: Consolidated Financials)

Quarterly \| Annual	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024
Total Income	122.94	155.82	131.57	106.46	88.59
Total Income Growth (%)	-21.10	18.43	23.58	20.17	14.06
Total Expenses	102.39	132.40	114.11	91.45	78.10
Total Expenses Growth (%)	-22.67	16.03	24.77	17.10	17.54
EBIT	20.54	23.42	17.46	15.01	10.49
EBIT Growth (%)	-12.27	34.11	16.32	43.06	-6.53
Profit after Tax (PAT)	15.75	17.69	13.00	11.11	7.63
PAT Growth (%)	-10.96	36.09	17.05	45.54	3.08
EBIT Margin (%)	16.71	15.03	13.27	14.10	11.84
Net Profit Margin (%)	12.82	11.36	9.88	10.43	8.62
Basic EPS (₹)	0.21	0.16	0.14	0.16	0.11

Quarterly \| Annual	Jun 2025	Mar 2025	Dec 2024	Sep 2024	Jun 2024
Total Income	122.57	155.37	130.85	105.68	88.14
Total Income Growth (%)	-21.11	18.73	23.83	19.89	15.77
Total Expenses	102.07	132.27	113.74	90.87	77.66
Total Expenses Growth (%)	-22.83	16.29	25.17	17.00	18.10
EBIT	20.50	23.10	17.12	14.81	10.48
EBIT Growth (%)	-11.26	34.93	15.57	41.28	1.01
Profit after Tax (PAT)	15.73	17.50	12.79	10.95	7.63
PAT Growth (%)	-10.13	36.83	16.81	43.54	13.04
EBIT Margin (%)	16.72	14.87	13.08	14.02	11.89
Net Profit Margin (%)	12.83	11.26	9.78	10.36	8.65
Basic EPS (₹)	0.21	0.16	0.14	0.16	0.11

Quarterly \| Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Total Revenue	482.45	276.91	238.85	231.66	187.61
Total Revenue Growth (%)	74.22	15.93	3.11	23.48	0.56
Total Expenses	416.94	242.94	212.29	205.50	171.73
Total Expenses Growth (%)	71.63	14.43	3.30	19.67	0.80
Profit after Tax (PAT)	49.43	25.31	20.07	19.79	10.53
PAT Growth (%)	95.28	26.13	1.42	87.87	1.72
Operating Profit Margin (%)	14.27	14.59	13.23	12.78	8.74
Net Profit Margin (%)	10.63	9.61	8.94	9.00	5.69
Basic EPS (₹)	0.57	0.34	0.24	0.26	0.13

Quarterly \| Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	480.04	271.46	239.25	231.66	251.95
Total Revenue Growth (%)	76.84	13.46	3.28	-8.05	19.56
Total Expenses	415.39	239.68	212.70	205.50	211.27
Total Expenses Growth (%)	73.31	12.68	3.50	-2.73	9.25
Profit after Tax (PAT)	48.87	23.62	20.07	19.79	29.17
PAT Growth (%)	106.88	17.70	1.42	-32.16	104.67
Operating Profit Margin (%)	14.15	14.02	13.21	12.52	16.72
Net Profit Margin (%)	10.55	9.14	8.93	9.00	11.91
Basic EPS (₹)	0.57	0.32	0.24	0.26	0.38

All figures in Rs Cr, unless mentioned otherwise

View Details

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Total Assets	413.28	404.66	377.83	308.24	180.17
Total Assets Growth (%)	2.13	7.10	22.58	71.08	2.72
Total Liabilities	71.12	116.52	121.82	86.02	62.82
Total Liabilities Growth (%)	-38.96	-4.35	41.62	36.93	-5.83
Total Equity	342.16	288.14	256.01	222.22	117.35
Total Equity Growth (%)	18.75	12.55	15.21	89.36	7.96
Current Ratio (x)	4.55	2.58	1.61	1.79	1.50
Total Debt to Equity (x)	0.01	0.25	0.32	0.26	0.11
Contingent Liabilities	0.00	-	-	-	5.45

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	409.69	391.50	376.94	308.24	291.65
Total Assets Growth (%)	4.65	3.86	22.29	5.69	61.56
Total Liabilities	69.78	105.05	120.93	86.02	104.07
Total Liabilities Growth (%)	-33.57	-13.13	40.58	-17.34	198.45
Total Equity	339.90	286.45	256.01	222.22	187.58
Total Equity Growth (%)	18.66	11.89	15.21	18.47	28.79
Current Ratio (x)	4.61	2.76	1.61	1.79	1.96
Total Debt to Equity (x)	0.01	0.25	0.32	0.26	0.33
Contingent Liabilities	0.00	0.55	6.18	3.04	2.10

All figures in Rs Cr, unless mentioned otherwise

View Details

Insights

Cash from Operations vs PAT
Operating cash flow of Rs 23.44 cr is 0.47 times compared to the reported net profit of Rs 49.43 cr. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Net Cash flow from Operating Activities	23.44	-5.96	10.53	16.33	13.84
Net Cash used in Investing Activities	-18.20	83.02	-44.95	-27.07	-17.68
Net Cash flow from Financing Activities	-67.90	-14.56	35.00	8.29	4.67
Net Cash Flow	-62.67	62.50	0.58	-2.45	0.83
Closing Cash & Cash Equivalent	0.71	63.38	0.88	0.30	6.52
Closing Cash & Cash Equivalent Growth (%)	-98.88	7,105.12	191.58	-95.37	14.50
Total Debt/ CFO (x)	0.20	-12.17	7.90	3.54	0.90

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	23.31	-5.94	10.50	16.33	-150.15
Net Cash used in Investing Activities	-18.38	83.83	-44.97	-27.07	75.46
Net Cash flow from Financing Activities	-67.59	-15.37	35.00	8.29	71.96
Net Cash Flow	-62.66	62.52	0.53	-2.45	-2.73
Closing Cash & Cash Equivalent	0.69	63.35	0.83	0.30	5.48
Closing Cash & Cash Equivalent Growth (%)	-98.91	7,560.28	174.20	-94.49	-33.27
Total Debt/ CFO (x)	0.17	-12.07	7.92	3.54	-0.41

All figures in Rs Cr, unless mentioned otherwise

View Details

Insights

ROE Outperforming 5 Year Average
Company delivered ROE of 14.37% in year ending Mar 31, 2025 outperforming its 5 year avg. of 10.95%. (Source: Standalone Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2017
Return on Equity (%)	14.44	8.78	7.83	8.90	8.97
Return on Capital Employed (%)	18.75	12.89	11.21	12.20	12.92
Return on Assets (%)	11.96	6.25	5.31	6.42	5.84
Interest Coverage Ratio (x)	82.74	9.65	10.93	16.62	57.38
Asset Turnover Ratio (x)	1.14	0.67	0.65	-	102.58
Price to Earnings (x)	31.35	41.67	27.70	46.51	14.62
Price to Book (x)	4.52	3.65	2.17	4.13	1.31
EV/EBITDA (x)	21.66	24.45	18.38	30.42	8.28
EBITDA Margin (%)	15.39	16.39	15.26	14.58	10.43

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	14.37	8.24	7.83	8.90	15.55
Return on Capital Employed (%)	18.62	12.22	11.21	11.96	21.00
Return on Assets (%)	11.92	6.03	5.32	6.42	10.00
Interest Coverage Ratio (x)	83.15	9.21	10.93	23.21	151.03
Asset Turnover Ratio (x)	1.16	0.67	0.66	0.73	83.93
Price to Earnings (x)	31.65	44.64	27.70	46.51	8.40
Price to Book (x)	4.55	3.67	2.17	4.13	1.31
EV/EBITDA (x)	21.92	25.75	18.39	30.97	5.40
EBITDA Margin (%)	15.27	15.85	15.23	14.31	18.37

Financial InsightsSyncom Form

Income (P&L)
Cash Flow
Ratios

- Quarterly Topline Performance
  Company witnessed QoQ revenue decline of 21.1%, which is lowest in the last 3 years. (Source: Consolidated Financials)
- Beating 3 Yr Revenue CAGR
  Company's annual revenue growth of 74.22% outperformed its 3 year CAGR of 27.39%. (Source: Consolidated Financials)
- Cash from Operations vs PAT
  Operating cash flow of Rs 23.44 cr is 0.47 times compared to the reported net profit of Rs 49.43 cr. (Source: Consolidated Financials)
- ROE Outperforming 5 Year Average
  Company delivered ROE of 14.37% in year ending Mar 31, 2025 outperforming its 5 year avg. of 10.95%. (Source: Standalone Financials)

Do you find these insights useful?

hate it
meh
love it

Syncom Form Technicals

Stock doesn't have any Buy/Sell Signals.
Price Analysis Data details are not available.
Pivot Levels
R1 R2 R3 PIVOT S1 S2 S3
Classic - - - - - - -
Average True Range
5 DAYS 14 DAYS 28 DAYS
ATR - - -

	R1	R2	R3	PIVOT	S1	S2	S3
Classic	-	-	-	-	-	-	-

	5 DAYS	14 DAYS	28 DAYS
ATR	-	-	-

Syncom Form Peer Comparison

CHART
TABLE

Choose from Peers
Choose from Stocks

NAME	1D	1W	1M	3M	1Y	3Y	5Y
Syncom Form Stock Performance	0.12	3.17	-5.69	-16.92	-25.51	0.00	0.00
Amrutanjan Health Care Stock Performance	-0.58	6.06	16.40	6.92	-5.52	4.53	76.18
SMS Pharma Stock Performance	3.40	3.53	8.90	-0.33	-26.97	194.67	199.00
Bliss GVS Pharma Stock Performance	-1.04	-2.44	-13.06	13.04	19.92	73.35	2.07
Jagsonpal Pharm Stock Performance	-0.03	0.22	-5.95	3.78	45.15	57.11	1566.16
Add More

Ratio Performance

NAME	P/E (x)	P/B (x)	ROE %	ROCE %	ROA %	Rev CAGR [3Yr]	OPM	NPM	Basic EPS	Current Ratio	Total Debt/ Equity (x)	Total Debt/ CFO (x)
Syncom Form	28.14	4.73	14.44	18.75	11.96	27.39	14.27	10.63	0.57	4.55	0.01	0.20
Amrutanjan Health Care	40.50	17.52	16.77	23.87	13.07	3.65	13.83	9.43	14.47	3.46	0.02	0.00
SMS Pharma	29.61	3.39	10.80	13.38	5.99	14.38	14.16	8.61	8.16	1.71	0.49	3.80
Bliss GVS Pharma	15.26	1.49	8.02	11.84	6.48	2.77	16.51	11.14	8.02	4.81	0.07	0.67
Jagsonpal Pharm	26.28	6.66	23.07	20.26	19.89	6.40	19.02	20.60	8.26	6.22	0.00	0.00
Add More

Annual Ratios (%)

Choose from Peers

Bajaj Healthcare
Lincoln Pharma
Themis Medicare
NGL Fine Chem
Wanbury Ltd

Choose from Stocks

See All Parameters

Peers InsightsSyncom Form

Do you find these insights useful?

hate it
meh
love it

Syncom Form Shareholding Pattern

Loading...
Showing Syncom Form Shareholding as on Jun 2025
Category Jun 2025 Mar 2025 Dec 2024 Sep 2024
Promoters 50.57 50.57 50.57 50.57
Pledge 0.00 0.00 0.00 0.00
FII 0.41 0.11 0.13 0.10
DII 0.00 0.00 0.00 0.00
Mutual Funds 0.00 0.00 0.00 0.00
Others 49.02 49.32 49.30 49.33
Showing Shareholding as on Jun 2025
Category No. of Shares Percentage % Change QoQ
Promoters 47,53,47,599 50.57 % 0.00
Pledge 0 0.00 % 0.00
FII 38,44,445 0.41 % 0.30
DII 17,224 0.00 % 0.00
MF 17,224 0.00 % 0.00
Others 46,07,90,732 49.02 % -0.29

Category	Jun 2025	Mar 2025	Dec 2024	Sep 2024
Promoters	50.57	50.57	50.57	50.57
Pledge	0.00	0.00	0.00	0.00
FII	0.41	0.11	0.13	0.10
DII	0.00	0.00	0.00	0.00
Mutual Funds	0.00	0.00	0.00	0.00
Others	49.02	49.32	49.30	49.33

Category	No. of Shares	Percentage	% Change QoQ
Promoters	47,53,47,599	50.57 %	0.00
Pledge	0	0.00 %	0.00
FII	38,44,445	0.41 %	0.30
DII	17,224	0.00 %	0.00
MF	17,224	0.00 %	0.00
Others	46,07,90,732	49.02 %	-0.29

Syncom Form MF Ownership

Motilal Oswal BSE Healthcare ETF-G
Equity: Sectoral-Pharma
- 0.02
  Amount Invested (in Cr.)
- 0.06295882%
  % of AUM
- 2.31
  % Change (MoM basis)
Bandhan BSE Healthcare Index Direct-G
Equity: Sectoral-Pharma
- 0.01
  Amount Invested (in Cr.)
- 0.06%
  % of AUM
- -3.85
  % Change (MoM basis)

MF Ownership as on 31 July 2025

View all Mutual Fund Schemes

Syncom Form Corporate Actions

Meeting Date	Announced on	Purpose	Details
Sep 29, 2025	Aug 11, 2025	AGM	-
Aug 08, 2025	Aug 04, 2025	Board Meeting	Quarterly Results & A.G.M.
May 19, 2025	May 13, 2025	Board Meeting	Audited Results
Feb 10, 2025	Feb 03, 2025	Board Meeting	Quarterly Results & Others
Nov 11, 2024	Nov 04, 2024	Board Meeting	Quarterly Results

Type	Dividend	Dividend per Share	Ex-Dividend Date	Announced on
Final	3%	0.03	Sep 09, 2022	Aug 16, 2022
Final	2%	0.02	Sep 21, 2017	May 31, 2017
Final	2%	0.02	Sep 22, 2016	May 31, 2016
Final	2%	0.02	Sep 16, 2015	Jun 01, 2015
Final	2%	0.02	Sep 18, 2014	Jun 02, 2014

All Types	Ex-Date	Record Date	Announced on	Details
Splits	Aug 19, 2013	Aug 20, 2013	Jul 08, 2013	Split: Old FV10.0\| New FV:1.0
Bonus	Aug 19, 2013	Aug 20, 2013	Jul 08, 2013	Bonus Ratio: 5 share(s) for every 2 shares held
Rights	May 13, 2009	May 20, 2009	Sep 01, 2008	Rights ratio: 1 share for every 2 held at a price of Rs 17.0

About Syncom Form

Syncom Formulation (India) Ltd., incorporated in the year 1988, is a Small Cap company (having a market cap of Rs 1,619.62 Crore) operating in Pharmaceuticals sector. Syncom Formulation (India) Ltd. key Products/Revenue Segments include Tablets, Injectables, Others, Plastic Granules, Capsules, Liquids, Raw Materials, Ointments, Export Incentives, Packing Materials (Traded), Dry Powders, Inhalers Traded for the year ending 31-Mar-2024. Show More

Executives
Auditors

KS
Kedarmal Shankarlal Bankda
Exe.Chairman & W T D
VS
Vijay Shankarlal Bankda
Managing Director
RA
Rinki Ankit Bankda
Whole Time Director
AJ
Ankit Jain
Independent Director
RK
Ritesh Kumar Lunkad
Independent Director
RJ
Ruchi Jindal
Independent Woman Director
AK
Ankit Kedarmal Bankda
Chief Financial Officer
VA
Vaishali Agrawal
Co. Secretary & Compl. Officer
Show More
Sanjay Mehta & Associates

Industry

Pharma - Indian

Key Indices Listed on

BSE SmallCap, BSE Healthcare, BSE AllCap, + 1 more

Address

7, Niraj Industrial Estate,Off Mahakali Caves Road,Mumbai, Maharashtra - 400093

Contact

finance@sfil.in

http://www.sfil.in

More Details

FAQs about Syncom Form share

1. What's the Syncom Form share price today?
As on 08 Sep, 2025, 03:59 PM IST Syncom Form share price is up by 0.12% basis the previous closing price of Rs 17.15. Syncom Form share price is Rs 17.23. Return Performance of Syncom Form Shares:
- 1 Week: Syncom Form share price moved up by 3.17%
- 3 Month: Syncom Form share price moved down by 16.92%
- 6 Month: Syncom Form share price moved up by 0.70%
2. What are the returns for Syncom Form share?
Return Performance of Syncom Form Shares:
- 1 Week: Syncom Form share price moved up by 3.17%
- 3 Month: Syncom Form share price moved down by 16.92%
- 6 Month: Syncom Form share price moved up by 0.70%
3. What's the market capitalization of Syncom Form?
Syncom Form share has a market capitalization of Rs 1,619.62 Cr. Within Pharmaceuticals sector, it's market cap rank is 73.
4. What is Syncom Form's 52 week high / low?
52 Week high of Syncom Form share is Rs 27.90 while 52 week low is Rs 14.10
5. What is the PE & PB ratio of Syncom Form?
The PE ratio of Syncom Form stands at 28.11, while the PB ratio is 4.73.

Trending in Markets

Top Gainers As on 03:59 PM | 08 Sep 2025

Suven Pharma 1,012.95

90.06 (9.76%)

Guj Mineral Dev.539.15

30.15 (5.93%)

Bharat Forge1,202.80

66.10 (5.82%)

Ashok Leyland137.29

6.52 (4.99%)

JP Power20.02

0.95 (4.99%)

Top Losers As on 03:57 PM | 08 Sep 2025

Amber Enterprises7,473.00

-320.50 (-4.12%)

EID Parry1,067.30

-45.50 (-4.09%)

Trent5,315.50

-213.00 (-3.86%)

Godfrey Philips10,657.00

-416.00 (-3.76%)

Coromandel Int.2,185.20

-72.71 (-3.22%)

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.

BrowseCompanies:

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

1 2 3 4 5 6 7 8 9

ETPrime

Syncom Formulation (India) Share Price

Syncom Form share price insights

InsightsSyncom Form

Key Metrics

Key Metrics

Syncom Form Share Price Returns

ET Stock ScreenersTop Score Companies

Syncom Form News & Analysis

Syncom Form Share Analysis

Unlock Stock Score, Analyst' Ratings & Recommendations

Syncom Form Share Recommendations

Syncom Form Financials

Insights

Insights

Insights

Financial InsightsSyncom Form

Syncom Form Technicals

Pivot Levels

Average True Range

Syncom Form Peer Comparison

Ratio Performance

Peers InsightsSyncom Form

Syncom Form Shareholding Pattern

Syncom Form MF Ownership

Motilal Oswal BSE Healthcare ETF-G

Bandhan BSE Healthcare Index Direct-G

Syncom Form Corporate Actions

About Syncom Form

Executives

Auditors

More Details

FAQs about Syncom Form share

Trending in Markets

Top Gainers As on 03:59 PM | 08 Sep 2025

Top Losers As on 03:57 PM | 08 Sep 2025

Syncom Form Quick Links

Equity Quick Links

More from Markets

1 Day	0.52%
1 Week	2.8%
1 Month	-5.69%
3 Months	-16.91%
1 Year	-25.45%
3 Years	97.82%
5 Years	939.16%